JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES) ›› 2015, Vol. 53 ›› Issue (6): 33-38.doi: 10.6040/j.issn.1671-7554.0.2014.944

Previous Articles     Next Articles

A microarray analysis of bortezomib-resistant gene expression in multiple myeloma

LIU Qiong1, PU Yedi2, DAI Guangxia1, MA Jiale1, YANG Jianxia1, LI Lizhen1, LI Hao1, WANG Luqun1   

  1. 1. Department of Hematology, Qilu Hospital of Shandong University, Jinan 250012, Shandong, China;
    2. Department of Hematology, Tianjin First Center Hospital, Tianjin 300192, China
  • Received:2014-12-11 Revised:2015-02-28 Online:2015-06-10 Published:2015-06-10

PDF (PC)

296

Abstract: Objective To investigate genes related to bortezomib-resistance phenotype by analyzing different gene expression patterns with cDNA microarray and explore the mechanism of bortezomib-resistant myeloma. Methods Gene expression profiles of KM3/BTZ and KM3 cell lines were compared using Affymetrix U133 plus 2.0 oligonucleotide microarray. Specific differently-expressed genes were chosen for further verification by real-time RT-PCR. Relevant data were analyzed with molecular annotation system MAS3.0 software and compared with documented resistance genes. Results It was found that the KM3/BTZ cell line had 670 differently expressed genes as compared to KM3, of which 32 genes were increased or decreased by more than 10 folds. These 32 genes were involved in the regulation of transcription and signal transduction. Some genes of ZNF and MS4A family and HSPB2 were lowly expressed in KM3, but highly expressed in KM3/BTZ. Except for JUN, 7 genes (CA12, CYP1B1, EPB41L3, HSPB2, MS4A4A, SDPR, PAWR) were further verified using real-time RT-PCR and results were consistent with the microarray. Conclusion Some members of ZNF and MS4A family and another 30 genes whose differential expression is more than 10 folds between KM3 and KM3/BTZ may be related to bortezomib-resistance in multiple myeloma cells. Combination of filteringgenes and detailed analysis of documented resistance genes provides a potential approach to investigate the mechanism of drug resistance in multiple myeloma cells.

Key words: Multiple myeloma, Drug resistance, Bortezomib, cDNA microarray

CLC Number: 

  • R733.3
[1] Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibitionin human multiple myeloma cells[J]. Proc Natl Acad Sci USA, 2002, 99(22):14374-14379.
[2] Zheng B, Zhou R, Gong Y, et al. Proteasome inhibitor bortezomib overcomes P-gp-mediated multidrug resistance in resistant leukemia cell lines[J]. Biochemical Int J Lab Hematol, 2012, 34(3):237-247.
[3] 蒲业迪, 李丽珍, 马道新, 等. 硼替佐米耐药多发性骨髓瘤细胞株KM3/BTZ的建立[J]. 山东大学学报:医学版, 2013, 51(2):33-36. PU Yedi, LI Lizhen, MA Daoxin, et al. Establishment of a bortezomib-resistant cell line KM3/BTZ of human multiple myeloma[J]. Journal of Shandong University:Health Sciences, 2013, 51(2):33-36.
[4] 李荣, 侯建. 新药时代造血干细胞移植治疗多发性骨髓瘤若干问题探讨[J]. 中国实用内科杂志, 2014, 34(2):115-117. LI Rong, HOU Jian. Several issues concerning hematopoietic stem cell transplantation in treatment of multiple myeloma in the new drugarea[J]. Chinese Journal of Practical Internal Medicine, 2014, 34(2):115-117.
[5] Palumbo A, Ambrosini MT, Benevolo G, et al. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma[J]. Blood, 2007, 109(7):2767-2772.
[6] Berenson JR, Yang HH, Sadler K, et al. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma[J]. J Clin Oncol, 2006, 24(6):937-944.
[7] Richardsom PG, Xie W, Jagannath S, et al. A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma[J]. Blood, 2014, 123(10):1461-1469.
[8] Chauhan D, Li G, Shringarpure R, et al. Blockade of Hsp27 overcomes bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells[J]. Cancer Res, 2003, 63(69):6174-6177.
[9] Oerlemans R, Franke NE, Assaraf YG, et al. Molecular basis of bortezomib resistance:proteasome subunit beta5(PSMB5) gene mutation and overexpression of PSMB5 protein[J]. Blood, 2008, 112(6):2489-2499.
[10] Carrasco DR, Sukhdeo K, Protopopova M, et al. The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis[J]. Cancer Cell, 2007, 411(4):349-360.
[11] Teru Hideshima, Klaus Podar, Dharminder Chauhan, et al. p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells[J]. Oncogene, 2004, 23(54):8766-8776.
[12] Wang BD, Kline CL, Pastor DM, et al. Prostate apoptosis response protein 4 sensitizes human colon cancer cells to chemotherapeutic 5-FU through mediation of an NF kappaB and microRNA network[J]. Mol Cancer, 2010, 430(9):1186-1476.
[13] Takagi Y, Nozaki K, Sugino T, et al. Phosphorylation of c-Jun NH(2)-terminal kinase and p38 mitogen-activated protein kinase after transient forebrain ischemia in mice[J]. Neurosci Lett, 2000, 294(2):117-120.
[14] Shringarpure R, Catley L, Bhole D, et al.Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib[J]. Br J Haematol, 2006, 134(2):145-156.
[15] Hoovers J, Mannens M, John R, et al. High-resolution localization of 69 potential human zinc finger protein genes:A number are clustered[J]. Genomics, 1992, 12(2):254-263.
[16] Huebner K, Druck T, Croce C, et al. Twenty-seven nonoverlapping zinc finger cDNAs from human T cells map to nine different chromosomes with apparent clustering[J]. Am J Hum Genet, 1991, 48(4):726-740.
[17] Duan Z, Choy E, Harmon D, et al. ZNF93 increases resistance to ET-743 (Trabectedin; Yondelis) and PM00104 (Zalypsis) in human cancer cell lines[J]. PLoS One, 2009, 6(9):728-732.
[18] Liang Y, Buckley TR, Tu L, et al. Structural organization of the human MS4A gene cluster on Chromosome 11q12[J]. Immunogenetics, 2001, 53(5):357-368.
[19] Liang Y, Tedder TF. Identification of a CD20-, FcepsilonRIbeta-, and HTm4 related gene family:sixteen new MS4A family members expressed in human and mouse[J]. Genomics, 2001, 72(2):119-127.
[20] Kutok JL, Yang X, Folkerth R, et al. Characterization of the expression of HTm4 (MS4A3), a cell cycle regulator, in human peripheral blood cells and normal and malignant tissues[J]. J Cell Mol Med, 2011, 15(1):86-93.
[1] GE Li-Juan, JIN Rui-Feng, WANG Ji-Wen, HU Xin-Sheng, LIKun. Association between the C1236T polymorphism in multi-drug resistance gene 1 and response to antiepileptic drug treatment in epileptic patients [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2209, 47(6): 99-102.
[2] MENG Wei, WU Dawei, SHAN Tichao, ZHANG Fan, GUO Haipeng, LIU Yu, DING Shifang, ZHAI Qian. Tigecycline in treating ventilator-associated pneumonia in critically ill patients [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(4): 71-75.
[3] GUO Hehe, SUN Zhiqiang, LIU Yanjuan, LIU Yichen, LI Guang, ZHENG Fang. Norcantharidin influences the expression of Notch signal pathway in multiple myeloma U226 cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(3): 32-37.
[4] YUAN Yuan, SI Heng, LIU Hongwei, LIU Chunhua, WANG Zhe, RUAN Yuhua, XING Hui. HIV drug resistance and the impact of antiretroviral therapy initiated at different stages among AIDS patiens [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(9): 77-81.
[5] LIU Zhenyan, HU Bin, BI Zhenwang, KOU Zengqiang, FANG Ming, CHEN Baoli, REN Yanyan, BI Zhenqiang. Antibiotic resistance on group A streptococcus among children in 4 cities of Shandong Province in 2013 [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(1): 77-80.
[6] ZHAI Shan-shan1, DING Bu-tong2, LI Hai-xia3, CHEN Yun1, CHANG Ya-li1, SANG Tan1, GUO Nong-jian1. Differential expressions of microRNAs in the CD138+ cells of multiple myeloma patients with deletion of chromosome 13 [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(5): 80-84.
[7] ZHANG Cheng-mei1， WU Chuan-tao1， ZHU Shan-shan2， JIA Shu3， WANG Yi4， Shi Yan-qiu1,2. Effect and mechanism of deacetyl-mycoepoxydiene on reversing resistance to taxol in tumor cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(4): 21-25.
[8] SUN Gao-ying1, WANG Xiao-yuan2, ZHANG Xiao-jin1, HAO Xiu-yu1， GUO Yuan-fang1, WANG Xiao1, BI Wen-xiang1. Effects of N-acetylcysteine  on resistance to paclitaxel in cervical carcinoma cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(3): 42-47.
[9] PU Ye-di, LI Li-zhen, MA Dao-xin, DONG Ke,ZHAO Chuan-li, SONG Qiang, WANG Lu-qun. Establishment of a bortezomib-resistant cell line KM3/BTZ of human multiple myeloma [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(2): 33-.
[10] WAN Yue, CHEN Shou-hua, GU He, ZHANG Li-li. Effects of bortezomib in combination with epirubicin on the
proliferation and apoptosis of breast cancer cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(2): 43-46.
[11] ZHANG Jing-jing1, WANG Zhe1, TIAN Yong-jie1, ZHANG Jie2. Effects of PJ34 on growth activity and cisplatin resistance of ovarian cancer C13* cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(1): 46-50.
[12] KAN Yan-yan1, ZHANG Jing-jing1, WANG Zhe1, TIAN Yong-jie1, QI Xiao-xia2, ZHANG Jie3. Effect of reduced expression of PARP-1 by RNA interference on cisplatin-resistance and proliferation in the ovarian cancer cell line [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2011, 49(4): 52-56.
[13] HAN Liping, FAN Juan, WANG Xin, ZHOU Fanghui, LIU xin, SUI Xiaohui. Expression and clinical relevance of ABCA3 in acute myeloid leukemia [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2010, 48(7): 108-111.
[14] LIU Huiya1, GAO Yanjing1, JIANG Dalei2, CHEN Haiying1. Effects of SPK1/S1P signal pathway on the apoptosis, invasiveness and multidrug resistance characteristics of human hepatocellular carcinoma cell line BEL-FU [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2010, 48(6): 67-71.
[15] KONG Shuai， LI Leping， JING Changqing, WANG Feng. The reversal effect on MDR1 gene-mediated multidrug resistance in human colon carcinoma LoVo/5-Fu cells by RNA interference [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2010, 48(6): 80-83.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd